BENITEC BIOPHAR/S (NASDAQ:BNTC) Upgraded at ValuEngine

ValuEngine upgraded shares of BENITEC BIOPHAR/S (NASDAQ:BNTC) from a hold rating to a buy rating in a research report sent to investors on Tuesday, ValuEngine reports.

BNTC traded down $0.14 during mid-day trading on Tuesday, reaching $5.31. 3,767 shares of the company traded hands, compared to its average volume of 4,397. The company’s fifty day moving average price is $2.48 and its 200-day moving average price is $1.27. BENITEC BIOPHAR/S has a 52-week low of $4.13 and a 52-week high of $24.00.

A hedge fund recently bought a new stake in BENITEC BIOPHAR/S stock. Sabby Management LLC acquired a new position in BENITEC BIOPHAR/S (NASDAQ:BNTC) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 1,365,615 shares of the biotechnology company’s stock, valued at approximately $971,000. BENITEC BIOPHAR/S accounts for approximately 0.5% of Sabby Management LLC’s portfolio, making the stock its 11th largest holding. Sabby Management LLC owned about 106.69% of BENITEC BIOPHAR/S at the end of the most recent reporting period.

BENITEC BIOPHAR/S Company Profile

Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference (ddRNAi) in Australia and the United States. The company provides BB-301, a single administration ddRNAi-based gene therapy for the treatment of oculopharyngeal muscular dystrophy; BB-201, a ddRNAi-based therapy for the treatment of wet age-related macular degeneration; and BB-101 and BB-103 ddRNAi-based therapies for the treatment of human hepatitis B.

See Also: Liquidity

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for BENITEC BIOPHAR/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BENITEC BIOPHAR/S and related companies with MarketBeat.com's FREE daily email newsletter.